Eiken Chemical Co., Ltd.TSE: 4549

Financial Results for Q2 FY2025 PDF

· Issued by Eiken Chemical Co., Ltd.
Financial Results for Q2 FY2025 (April 1, 2025 to September 30, 2025) EIKEN CHEMICAL CO., LTD. (Code: 4549)


October 30, 2025


  1. Financial Results for Q2 FY2025

  2. Initiatives to Enhance ROIC - Progress Update

  3. Topics

Index



2



Financial Results for Q2 FY2025


3



Financial Results for Q2 FY2025

Executive Summary

  • External Environment

    • The impact of soaring global commodity prices, geopolitical risks, U.S. trade policies, and monetary policies of major countries

    • Continued rise in costs such as logistics and raw material procurement

  • The Company's Business Results

    • Sales and profit increased, driven mainly by strong performance in fecal immunochemical test (FIT) reagents, urinalysis and medical devices for overseas market

    • Recorded a special gain from the transfer of shares in a consolidated subsidiary

  • Other

  • Relocated head office from Taito-ku to "Ochanomizu Sola City" in Chiyoda-ku, Tokyo

  • Established a local subsidiary in China for marketing and research

  • Participated in TICAD9 (the 9th Tokyo International Conference on African Development) to promote the value



of products such as TB-LAMP in Africa

  • Retired 4 million treasury shares

4



Q2 FY2024

Q2 FY2025

Amount of

Percentage of

FY2025 Forecast

Results

Results

Change

Change

Amount

Progress rate

Net sales

19,729

20,430

700

3.6%

42,200

48.4%

Cost of sales

11,522

12,059

536

4.7%

25,150

47.9%

Gross profit

8,207

8,371

164

2.0%

17,050

49.1%

SG&A expenses

6,640

6,642

2

0.0%

13,800

48.1%

Operating profit

1,566

1,729

162

10.4%

3,250

53.2%

Ordinary profit

1,698

1,730

31

1.9%

3,100

55.8%

Net profit

1,309

2,979

1,670

127.5%

3,770

79.0%

R&D expenses

2,036

1,875

(161)

(7.9%)

4,040

46.4%

Financial Results for Q2 FY2025

Consolidated Financial Results-YoY Change

Millions of yen



  • Sales and profit increased, driven mainly by strong performance in FIT reagents, urinalysis and medical devices for

    overseas market

  • Recorded a special gain of ¥2 billion from the transfer of shares in a consolidated subsidiary

  • No change to the full-year earnings forecast

5



Financial Results for Q2 FY2025

Sales Results by Region -YoY Change

百万 円

Fecal immunochemical tests (FIT)

セ

メ

ト

ン

6,613

6,858

244

3.7%

13,640

50.3%

4,870

4,886

16

0.3%

9,680

50.5%

Immunological and serological excluding FIT

Q2 FY2024

Results

Q2 FY2025

Results

別

Amount of Change

Percentage 位

金額 単

：

売

上高

上

of Change

Millions of yen

Urinalysis

グ 2,293 2,362

69 3.0%

高4,740 49.8%

Microbiological 2,194 2,148

Clinical chemistry test 295 300

(45) (2.1%) 4,900 43.8%

4 1.6% 610 49.2%

Equipment/ Food and

Environment

1,001 949

(51) (5.2%) 1,860 51.1%

Molecular test

712

1,012

299

42.0%

2,440

41.5%

Medical devices/Others

1,748

1,912

163

9.4%

4,330

44.2%

Total

19,729

20,430

700

3.6%

42,200

48.4%

FY2025 Forecast

Amount

Progress rate



  • Overseas sales of FIT, Urinalysis, and medical devices remained strong

  • Molecular test segment saw increased revenue due to temporary royalty income

  • TB-LAMP orders from Nigeria resumed, but the impact of USAID program closure continues



1,566

Impact of increase in sales

Increase in cost

of sales

The Cost of Sales Ratio

58.4% (Q2 FY2024)

↓

59.0% (Q2 FY2025)

+701

-536

-2

Q2 FY2024

Results

Q2 FY2025

Results

Operating profit margin

7.9%

Operating profit margin

8.5%

Financial Results for Q2 FY2025

Breakdown of Operating Profit

Millions of yen

700

Increase in SG&A expense

1,729

536



Operating profit improved compared to the same period last year, driven by sales growth and efficient expense management

The cost of sales ratio increased due to rising logistics and raw material procurement costs

7



Financial Results for Q2 FY2025

Sales Results by Region -YoY Change

2,109

1,216

EMEA

Americas

1,243

2,123

APAC

1,715

1,938

Americas: North and Central/South America

Millions of yen

Q2 FY2024

Results

Q2 FY2025

Results

Amount of Change

Percentage of Change

Domestic

Sales

14,831

14,981

149

1.0%

Overseas Sales

4,898

5,449

551

11.3%

Overseas Sales

Ratio

24.8%

26.7%

-

-

Total

19,729

20,430

700

3.6%

30,150 49.7%

12,050 45.2%

－ －

42,200 48.4%

(27) (2.2%) 2,530 48.1%

393 22.9% 5,260 40.1%

185 9.6% 4,260 49.8%

Overseas sales increased due to FIT reagents and devices in major countries compensating for the decline in TB-LAMP

(Americas)

  • Despite a slight dip in sales, the trend of increasing demand continues due to the expansion of the target age group, endoscopic triage, and the shift from chemical methods to immunochemical methods

    (EMEA)

  • Continuously acquired national screening programs in England and France England：Starting in July 2026

    France ：Starting in January 2026

    In France, distribution of sampling bottles to all eligible individuals

  • FIT sales recovered from last year's temporary decline, with steady growth across countries driven by expanding target age groups and increasing sampling bottle distribution

  • Sales of TB-LAMP delayed due to USAID program closure

    (APAC)

  • Sales of urinalysis and devices remains stable

EMEA: Europe, Africa, the Middle East, and Russia (TB-LAMP for developing countries is included in the EMEA region)

APAC: Asia and Oceania [All sales of overseas urinalysis test strips (in partnership with Sysmex Corporation) are included in the APAC region]

8

FY2025 Forecast

Amount

Progress rate





Initiatives to Enhance ROIC - Progress Update


9



Measures

Operating profit margin Improvement target

for FY2027

Progress in Q2 FY2025

Cost reductions

  • Focus investment in main, profitable and

    developing product groups

  • Launch and expansion of new and improved

    products

  • Liquidate and withdraw from low-earning product groups

  • Consolidate and eliminate product dosage

    forms

  • Increase accuracy of demand forecasts

  • Reduce plant loss costs

  • Consolidate production sites for urinalysis tests and immunological and serological tests into Nogi Plant

  • Work toward data-driven smart factories

＋2.0 pt

  • Launched sales enhancement measures for earning products POCT (Adenovirus and Streptococcus A)

  • Increased sales of core product FIT due to expanded target age group in overseas markets

  • Sales growth in the EMEA region driven by expanded promotion of Calprotectin

  • Improved cost of sales by revising prices of 137 low earning products, including powdered media and instruments, to appropriate market levels

  • Consolidated production of urine test reagents from China to Nogi Plant, improving cost of sales for urine test strips

SG&A

expense reductions

  • Optimize outsourced research expenses

    based on product portfolio

  • Optimize staffing structures and plans to

raise labor productivity

＋3.2 pt

  • Personnel cost ratio to sales: down 0.6pt YoY

Initiatives to Enhance ROIC - Progress Update

Strengthening Earning Power



(Ref.) Operating Profit Margin FY2025 Actual: 7.4% → FY2028 Target: 12.6%

10



Earlier from Eiken Chemical

All Eiken Chemical news releases